Skip to main content
CING
NASDAQ Life Sciences

Cingulate的CTx-1301获得关键专利，NDA进展到五月PDUFA，1,200万美元私募发行完成

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$11.6
Mkt Cap
$127.546M
52W Low
$3.2
52W High
$11.89
Market data snapshot near publication time

summarizeSummary

Cingulate Inc.在其2025年第四季度和全年财务报告中宣布了一系列重要的运营里程碑。最值得注意的是，公司为其首要的多动症药物候选物CTx-1301获得了美国专利许可通知，并获得了欧洲专利授权，延长了知识产权保护至2042年五月。FDA已经接受了CTx-1301的新药申请（NDA）进行审查，设定了处方药用户费法（PDUFA）目标行动日期为2026年五月31日，尽管有一些对额外制造和CMC信息的请求。另外，Cingulate成功地完成了1,200万美元的私募发行，增强了其财务基础，并任命了一名首席商务官以推进商业准备。这些发展，特别是加强的专利财产和CTx-1301的明确监管途径，对于这家生物制药公司来说至关重要，提供了显著的降风险和明确的近期催化剂。投资者现在将关注FDA关于CTx-1301的决定，预计在PDUFA截止日期前作出。

在该公告发布时，CING的交易价格为$11.60，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.3亿。 52周交易区间为$3.20至$11.89。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CING - Latest Insights

CING
Apr 28, 2026, 4:24 PM EDT
Filing Type: 424B3
Importance Score:
8
Cingulate Registers 4.2 Million Shares for Resale from Prior Private Placement, Creating Significant Market Overhang
Sentiment: Negative
View Wiseek Article
CING
Apr 14, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
8
Cingulate Registers Resale of 4.2M Shares from Private Placement, Creating Significant Market Overhang
Sentiment: Negative
View Wiseek Article
CING
Mar 27, 2026, 4:01 PM EDT
Filing Type: 424B3
Importance Score:
8
Cingulate Finalizes Prospectus for Resale of 3.5M Shares Under Existing Lincoln Park Equity Line
Sentiment: Negative
View Wiseek Article
CING
Mar 26, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Falcon Creek Group Finalizes $11M Investment in Cingulate, Securing 28.5% Stake and Board Seats
Sentiment: Positive
View Wiseek Article
CING
Mar 24, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
Cingulate Inc. Establishes $100M At-The-Market Offering and Secures Shareholder Approval for Prior Issuances
Sentiment: Negative
View Wiseek Article
CING
Mar 24, 2026, 5:13 PM EDT
Filing Type: 424B3
Importance Score:
9
Cingulate Inc. Finalizes Terms for Highly Dilutive $100M At-The-Market Offering
Sentiment: Negative
View Wiseek Article
CING
Mar 19, 2026, 6:00 PM EDT
Filing Type: S-3
Importance Score:
8
Cingulate Inc. Registers Additional 3.5M Shares for Resale Under Existing Equity Line, Potentially Adding 30% Dilution
Sentiment: Negative
View Wiseek Article
CING
Mar 18, 2026, 4:30 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Cingulate Inc. Corrects Proxy Statement, Disclosing New 18.16% Beneficial Owner
Sentiment: Neutral
View Wiseek Article
CING
Mar 18, 2026, 8:13 AM EDT
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Going Concern, FDA Manufacturing Issues for Lead Drug, and Dilutive Financing
Sentiment: Negative
View Wiseek Article
CING
Mar 18, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Cingulate Secures Key Patents for Lead ADHD Asset CTx-1301 and Closes $12M Insider-Backed Financing
Sentiment: Positive
View Wiseek Article